Polymer-free sirolimus-based submicron carrier-eluting stent: present and future perspective.

Area of Science:

• Cardiovascular Medicine
• Biomaterials Science
• Interventional Cardiology

Background:

• Newer drug-eluting stents (DES) still face late adverse events, driving innovation in stent technology.
• Current DES designs often rely on polymers, which can contribute to late complications.
• There is a need for advanced stent platforms that combine the benefits of DES and drug-coated balloons (DCB).

Purpose of the Study:

• To review the concept, preclinical data, and early clinical experience of a novel polymer-free sirolimus-based submicron carrier-eluting stent (Abluminus np).
• To discuss ongoing clinical trials evaluating this innovative stent technology.
• To highlight the unique features of this stent, including its hybrid design and drug delivery mechanism.

Main Methods:

• The Abluminus np stent features a polymer-free, thin-strut cobalt-chromium platform with an abluminal phospholipid submicron carrier coating.
• Fusion coating extends drug delivery to stent shoulders and exposed balloon surfaces.
• Preclinical studies assessed endothelialization, inflammation, and drug elution.
• Early clinical data from 'all-comers' and pilot trials (e.g., STARS DAPT) were analyzed.

Main Results:

• Preclinical studies showed rapid endothelialization, minimal inflammation, and complete sirolimus elution by 40 days.
• Preliminary clinical data in 'all-comers' demonstrated low rates of major adverse cardiovascular events and no stent thrombosis at 12 months.
• The STARS DAPT pilot trial is investigating abbreviated dual antiplatelet therapy regimens for ST-elevation myocardial infarction patients.

Conclusions:

• The polymer-free sirolimus-based submicron carrier DES represents a novel approach integrating DES and DCB functionalities.
• Early preclinical and clinical findings suggest favorable safety and efficacy profiles.
• Further large-scale randomized trials are necessary to establish definitive evidence for this innovative coronary stent technology.